Nadia Harbeck spends much of her time researching Internal medicine, Breast cancer, Oncology, Cancer and Surgery. Her work in Internal medicine covers topics such as Placebo which are related to areas like Bevacizumab and Aromatase inhibitor. Her Breast cancer study integrates concerns from other disciplines, such as Adjuvant therapy, Gynecology and Clinical trial, Pathology.
Her Oncology research includes themes of Plasminogen activator inhibitor-1, Trastuzumab, Mammary gland, Palbociclib and Clinical endpoint. Her Cancer research includes elements of Cancer research and Endocrinology. Her work deals with themes such as Adverse effect, General surgery and Breast disease, which intersect with Surgery.
Her primary scientific interests are in Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. The study incorporates disciplines such as Gynecology and Surgery in addition to Internal medicine. Her Breast cancer research is multidisciplinary, relying on both Family medicine, Clinical trial, Disease and Docetaxel.
Nadia Harbeck works mostly in the field of Oncology, limiting it down to topics relating to Palbociclib and, in certain cases, Fulvestrant and Letrozole. Her studies in Cancer integrate themes in fields like Biomarker, Cancer research and Pathology. Her biological study spans a wide range of topics, including Gastroenterology, Triple-negative breast cancer and Anthracycline.
Nadia Harbeck focuses on Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Her work on Early breast cancer, Metastatic breast cancer, Endocrine therapy and Triple-negative breast cancer as part of her general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. Her Metastatic breast cancer study combines topics in areas such as Targeted therapy, Capecitabine and Phases of clinical research.
Her Oncology research integrates issues from Pembrolizumab, Abemaciclib, Trastuzumab and Adjuvant therapy. Her studies deal with areas such as Quality of life, Family medicine, Placebo, Hazard ratio and Gemcitabine as well as Breast cancer. Cancer is closely attributed to Mutation testing in her research.
Nadia Harbeck mostly deals with Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. Her research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Hazard ratio and Placebo. Her Adjuvant study in the realm of Oncology interacts with subjects such as Vinorelbine.
Her Breast cancer research is multidisciplinary, incorporating elements of Gemcitabine and Clinical trial. Her Chemotherapy research incorporates elements of Taxane and Anthracycline. Her Cancer research is multidisciplinary, incorporating perspectives in Research design and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés.
Journal of Clinical Oncology (2010)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso;A. Costa;L. Norton;E. Senkus.
Annals of Oncology (2014)
Triple-negative breast cancer—current status and future directions
O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai.
Annals of Oncology (2009)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck.
Journal of the National Cancer Institute (2001)
(Impact Factor: 2.268)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: